Diretrizes brasileiras para o diagnóstico e tratamento de candidemia e candidíase invasiva em adultos e crianças
InfectologiaResumo original em inglês
O que aconteceu
Invasive candidiasis, including candidemia and deep-seated Candida infections, remains a major cause of morbidity and mortality in hospitalized patients worldwide, particularly in low- and middle-income countries. In Brazil, candidemia is associated with persistently high mortality rates, driven by late diagnosis, limited access to antifungal agents, and heterogeneous diagnostic capacity. The last national guideline issued by the Brazilian Society of Infectious Diseases (SBI) was published in 2013, and substantial advances have occurred since then in epidemiology, diagnostics, and antifungal therapy.
To provide an updated, evidence-based Brazilian guideline for the diagnosis and treatment of candidemia and invasive candidiasis in adults and children, incorporating contemporary scientific data and addressing the specific epidemiological, diagnostic, and therapeutic realities of Brazil.
This guideline was developed by the SBI Mycology Committee through a structured consensus process. Clinical questions were formulated using the PICO framework, followed by systematic literature searches of PubMed-indexed studies and international guidelines. Recommendations were contextualized according to Brazilian epidemiology, laboratory infrastructure, and access to antifungal therapies.
O que encontraram
Key updates include revised epidemiological data from Brazilian cohorts, updated recommendations for blood culture strategies and non-culture-based diagnostics, refined indications for echocardiography and fundoscopy, and updated therapeutic algorithms. Novel antifungal agents, including long acting echinocandins such as rezafungin, are discussed. Emphasis is placed on early echinocandin therapy, timely source control, antifungal stewardship, and infectious diseases consultation.
Por que isso importa
This updated Brazilian guideline reflects current scientific evidence while addressing national healthcare realities, aiming to standardize care, improve outcomes, and reduce mortality associated with invasive candidiasis in Brazil.
Resumo publicado sob licença CC BY. A tradução para o português ainda não chegou a este estudo.
O estudo original
Brazilian guidelines for the diagnosis and treatment of candidemia and invasive candidiasis in adults and children
Arnaldo L Colombo, Marcello M C Magri, Fabianne Carlesse, Diego R Falci, Marcia Garnica, Daniel W C L Santos, Flavio Queiroz Telles, Alessandro C Pasqualotto
Descritores MeSH
- Antifungal Agents
- Candidiasis, Invasive
- Candidemia
- Humans
- Child
- Brazil
- Adult
Veja também
Estudos relacionados
- Candida (Candidozyma) auris in pediatric population: risk factors, clinical presentation, and outcomes
- Systematic Review of Candidemia in Brazil: Unlocking Historical Trends and Challenges in Conducting Surveys in Middle-Income Countries
- Comparative efficacy and safety of systemic antifungal agents for candidemia: a systematic review with network meta-analysis and multicriteria acceptability analyses
- Comparative effectiveness of amphotericin B, azoles and echinocandins in the treatment of candidemia and invasive candidiasis: A systematic review and network meta-analysis